News | November 23, 2024
Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Subscribe To Our Newsletter & Stay Updated
